Latest gross profit for RADLY: $13B, below the Healthcare sector average of $66B.
Get informed when a big investor buys or sells
+ FollowAs of Jun 30, 2026
Trailing 12 months ending Jun 30, 2026
Raia Drogasil S.A. (RADLY) currently reports a gross profit of $13B as of June 2026. That compares with $12B in the prior-year period — up 4.0% year over year. That is below the Healthcare sector average of $66B. Use the charts on this page to explore Raia Drogasil S.A.'s gross profit history and peer comparisons.
Raia Drogasil S.A.'s gross profit increased from $12B to $13B — a 4.0% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Raia Drogasil S.A.'s gross profit of $13B is lower than the Healthcare sector average of $66B. That is roughly 80.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
Raia Drogasil S.A. reported $13B in gross profit as of June 2026. That compares with $12B in the prior-year period — up 4.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current gross profit of $13B, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $66B. From there, open related valuation or income-statement pages for Raia Drogasil S.A., and consider following RADLY for alerts when major investors trade the stock.